|
Eprosartan
Eprosartan
|
| (IUPAC) ime
|
| 4-({2-Butil-5-[2-karboksi-2-(tiofen-2-ilmetil)et-1-en-1-il]-1H-imidazol-1-il}metil)benzojeva kiselina
|
| Klinički podaci
|
| Robne marke
|
Teveten
|
| AHFS/Drugs.com
|
Monografija
|
| MedlinePlus
|
a601237
|
| Identifikatori
|
| CAS broj
|
133040-01-4
|
| ATC kod
|
C09CA02
|
| PubChem[1][2]
|
5281037
|
| DrugBank
|
DB00876
|
| ChemSpider[3]
|
4444504
|
| UNII
|
2KH13Z0S0Y  Y
|
| KEGG[4]
|
D04040 Y
|
| ChEBI
|
CHEBI:4814 Y
|
| ChEMBL[5]
|
CHEMBL813 Y
|
| Hemijski podaci
|
| Formula
|
C23H24N2O4S
|
| Mol. masa
|
Eprosartan mesilat: 520,625 g/mol
|
| SMILES
|
eMolekuli & PubHem
|
| InChI |
|---|
InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ Y
Key: OROAFUQRIXKEMV-LDADJPATSA-N Y |
|
| Farmakokinetički podaci
|
| Bioraspoloživost
|
15% (Eprosartan mesilat)
|
| Metabolizam
|
ne metabolizuje se
|
| Poluvreme eliminacije
|
5 do 9 Sati
|
| Izlučivanje
|
Renalno 10%, bilijarno 90%
|
| Farmakoinformacioni podaci
|
| Trudnoća
|
?
|
| Pravni status
|
|
| Način primene
|
Oralno
|
Eprosartan je antagonist angiotenzin II receptora koji se koristi za tretiranje visokog krvnog pritiska. Preduzeće Abbott Laboratories prodaje ovaj lek pod imenom Teveten u SAD i većini drugih zemalja. Preduzeće INTAS Pharmaceuticals ga prodaje pod imenom Eprozar u Indiji. U jednoj od formulacija se eprosartan zajedno sa hidrohlorotiazidom prodaje kao Teveten HCT (SAD) i TevetenPlus.
Poput drugih antagonista angiotenzin II receptora, eprosartan je generalno bolje tolerisan od enalaprila (ACE inhibitora), posebno među osobama u godinama.[6]
Osobine
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
- ↑ Ruilope L, Jäger B, Prichard B (2001). „Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial”. Blood Press. 10 (4): 223–9. DOI:10.1080/08037050152669747. PMID 11800061.
- ↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o.
- ↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573. edit
- ↑ Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286. edit
Spoljašnje veze
|
|
